JP5723381B2 - Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 - Google Patents
Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 Download PDFInfo
- Publication number
- JP5723381B2 JP5723381B2 JP2012538997A JP2012538997A JP5723381B2 JP 5723381 B2 JP5723381 B2 JP 5723381B2 JP 2012538997 A JP2012538997 A JP 2012538997A JP 2012538997 A JP2012538997 A JP 2012538997A JP 5723381 B2 JP5723381 B2 JP 5723381B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- mmol
- fluoro
- pyran
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010020615 nociceptin receptor Proteins 0.000 title description 36
- 239000002464 receptor antagonist Substances 0.000 title description 4
- 229940044551 receptor antagonist Drugs 0.000 title description 4
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 210
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 148
- -1 chloro, cyano, cyanomethyl Chemical group 0.000 claims description 97
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 40
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 17
- 208000008589 Obesity Diseases 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 206010033307 Overweight Diseases 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000019695 Migraine disease Diseases 0.000 claims description 8
- 206010027599 migraine Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 7
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- ALDFBAMFJCZMRT-UHFFFAOYSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 ALDFBAMFJCZMRT-UHFFFAOYSA-N 0.000 claims description 3
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims description 2
- QTOTZWFQCWGMHS-UHFFFAOYSA-N 2-chloro-1'-[[1-(2,6-difluorophenyl)-3-methylpyrazol-4-yl]methyl]-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1F QTOTZWFQCWGMHS-UHFFFAOYSA-N 0.000 claims description 2
- RBBAMCYZDBRGRI-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-[2-fluoro-6-(2-methylimidazol-1-yl)phenyl]-3-methylpyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1N1C=CN=C1C RBBAMCYZDBRGRI-UHFFFAOYSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 193
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 160
- 239000000203 mixture Substances 0.000 description 124
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 106
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 93
- 239000000243 solution Substances 0.000 description 93
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 84
- 239000002904 solvent Substances 0.000 description 74
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 58
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- 238000002360 preparation method Methods 0.000 description 50
- 239000012071 phase Substances 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000012044 organic layer Substances 0.000 description 37
- 238000004587 chromatography analysis Methods 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 31
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 30
- 238000012360 testing method Methods 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 28
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 28
- 235000017557 sodium bicarbonate Nutrition 0.000 description 28
- 102000048266 Nociceptin Human genes 0.000 description 27
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 27
- 235000019341 magnesium sulphate Nutrition 0.000 description 27
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 229910052938 sodium sulfate Inorganic materials 0.000 description 26
- 235000011152 sodium sulphate Nutrition 0.000 description 26
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000000725 suspension Substances 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 239000003480 eluent Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 108090000622 Nociceptin Proteins 0.000 description 21
- 229920006395 saturated elastomer Polymers 0.000 description 20
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 239000000700 radioactive tracer Substances 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 150000003892 tartrate salts Chemical class 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 239000013058 crude material Substances 0.000 description 16
- 238000012799 strong cation exchange Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 102100028646 Nociceptin receptor Human genes 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- YYNOJCBVROUTEB-UHFFFAOYSA-N 2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=2SC(Cl)=CC=2C(F)(F)COC21CCNCC2 YYNOJCBVROUTEB-UHFFFAOYSA-N 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- 238000011813 knockout mouse model Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 239000000935 antidepressant agent Substances 0.000 description 9
- 229940005513 antidepressants Drugs 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 208000032841 Bulimia Diseases 0.000 description 8
- 206010006550 Bulimia nervosa Diseases 0.000 description 8
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 6
- NWDMGTFNIOCVDU-UHFFFAOYSA-N 5-methyl-1h-pyrazole-4-carbaldehyde Chemical compound CC=1NN=CC=1C=O NWDMGTFNIOCVDU-UHFFFAOYSA-N 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- 206010015866 Extravasation Diseases 0.000 description 6
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000036251 extravasation Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000003642 hunger Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 5
- 208000020401 Depressive disease Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002032 methanolic fraction Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 5
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- SDSPIIZCESWAIR-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[(5-methyl-1h-pyrazol-4-yl)methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound CC1=NNC=C1CN1CCC2(C=3SC(Cl)=CC=3C(F)(F)CO2)CC1 SDSPIIZCESWAIR-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000005708 Sodium hypochlorite Substances 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001951 dura mater Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000000427 trigeminal ganglion Anatomy 0.000 description 4
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
- QRNGMOREKMNTGF-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-3-methylpyrazole Chemical compound N1=C(C)C=CN1C1=C(F)C=CC=C1F QRNGMOREKMNTGF-UHFFFAOYSA-N 0.000 description 3
- PARZYDWSHCPAMV-UHFFFAOYSA-N 1-[2-fluoro-6-(1-methylimidazol-2-yl)phenyl]-3-methylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1C1=NC=CN1C PARZYDWSHCPAMV-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 3
- QZQYLBAKQQZEPK-UHFFFAOYSA-N 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-n,n-dimethylpropanamide Chemical compound C1CC2(C=3SC(F)=CC=3CCO2)CCN1CC(C(=O)N(C)C)CC1=CC=CC=C1F QZQYLBAKQQZEPK-UHFFFAOYSA-N 0.000 description 3
- ZIJGUDNMWJNPJV-UHFFFAOYSA-N 2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorobenzonitrile Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C#N ZIJGUDNMWJNPJV-UHFFFAOYSA-N 0.000 description 3
- KMBVWIOHNSLQKY-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-(2-fluoro-6-nitrophenyl)-3-methylpyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1[N+]([O-])=O KMBVWIOHNSLQKY-UHFFFAOYSA-N 0.000 description 3
- JWRJYELIMAXNIL-UHFFFAOYSA-N 2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=2SC(F)=CC=2CCOC21CCNCC2 JWRJYELIMAXNIL-UHFFFAOYSA-N 0.000 description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- JERQDPGTERPYQK-UHFFFAOYSA-N ethyl 2-[(2,6-difluorophenyl)hydrazinylidene]propanoate Chemical compound CCOC(=O)C(C)=NNC1=C(F)C=CC=C1F JERQDPGTERPYQK-UHFFFAOYSA-N 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- ZKRRTJNMCFRJKL-UHFFFAOYSA-N methyl n-[3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)phenyl]carbamate Chemical compound COC(=O)NC1=CC=CC(F)=C1N1N=C(C)C(C=O)=C1 ZKRRTJNMCFRJKL-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- CJYQZTZSYREQBD-UHFFFAOYSA-N n-fluorobenzenesulfonamide Chemical compound FNS(=O)(=O)C1=CC=CC=C1 CJYQZTZSYREQBD-UHFFFAOYSA-N 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- MDNZMMUPULKBQD-UHFFFAOYSA-N tert-butyl 3-[(2-fluorophenyl)hydrazinylidene]butanoate Chemical compound CC(C)(C)OC(=O)CC(C)=NNC1=CC=CC=C1F MDNZMMUPULKBQD-UHFFFAOYSA-N 0.000 description 3
- FRBBAEFPFAJBAU-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)phenyl]methyl]carbamate Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1CN(C(=O)OC(C)(C)C)C1CC1 FRBBAEFPFAJBAU-UHFFFAOYSA-N 0.000 description 3
- OQBZXQKRSGAFQD-LREBCSMRSA-N (2R,3R)-2,3-dihydroxybutanedioic acid 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N,N-dimethylpropanamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CC2(C=3SC(F)=CC=3CCO2)CCN1CC(C(=O)N(C)C)CC1=CC=CC=C1F OQBZXQKRSGAFQD-LREBCSMRSA-N 0.000 description 2
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 2
- KCKTYCCHSDKBOJ-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-3-methylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1F KCKTYCCHSDKBOJ-UHFFFAOYSA-N 0.000 description 2
- IZKOUIKISYEPJH-UHFFFAOYSA-N 1-(2,6-dimethylphenyl)-3-methylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(C)=NN1C1=C(C)C=CC=C1C IZKOUIKISYEPJH-UHFFFAOYSA-N 0.000 description 2
- MFHWBICLXFAOPC-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-(methoxymethyl)pyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(COC)=NN1C1=CC=CC=C1F MFHWBICLXFAOPC-UHFFFAOYSA-N 0.000 description 2
- IXDRRXIJOCJSSX-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-(methoxymethyl)pyrazole-4-carboxylic acid Chemical compound C1=C(C(O)=O)C(COC)=NN1C1=CC=CC=C1F IXDRRXIJOCJSSX-UHFFFAOYSA-N 0.000 description 2
- JGGCJVLIEAYPPX-UHFFFAOYSA-N 1-[2-[(dimethylamino)methyl]phenyl]-3-methylpyrazole-4-carbaldehyde Chemical compound CN(C)CC1=CC=CC=C1N1N=C(C)C(C=O)=C1 JGGCJVLIEAYPPX-UHFFFAOYSA-N 0.000 description 2
- VPCRVDXLPCCHMH-UHFFFAOYSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]cyclopropan-1-amine Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C1(N)CC1 VPCRVDXLPCCHMH-UHFFFAOYSA-N 0.000 description 2
- QNJASCCBDIAEPG-UHFFFAOYSA-N 1-[2-fluoro-6-(methoxymethyl)phenyl]-3-methylpyrazole-4-carbaldehyde Chemical compound COCC1=CC=CC(F)=C1N1N=C(C)C(C=O)=C1 QNJASCCBDIAEPG-UHFFFAOYSA-N 0.000 description 2
- NFJWQIHSHUPPPT-UHFFFAOYSA-N 1-[2-fluoro-6-(morpholin-4-ylmethyl)phenyl]-3-methylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1CN1CCOCC1 NFJWQIHSHUPPPT-UHFFFAOYSA-N 0.000 description 2
- JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 2
- GKPHNZYMLJPYJJ-UHFFFAOYSA-N 2,3-difluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1F GKPHNZYMLJPYJJ-UHFFFAOYSA-N 0.000 description 2
- UDRRAFLRLIHHCM-UHFFFAOYSA-N 2,4,4-trifluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound S1C(F)=CC(C(CO2)(F)F)=C1C12CCNCC1 UDRRAFLRLIHHCM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GDZYGSIPEUGQID-UHFFFAOYSA-N 2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine];hydrochloride Chemical compound Cl.C1=2SC(Cl)=CC=2C(F)(F)COC21CCNCC2 GDZYGSIPEUGQID-UHFFFAOYSA-N 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- CUTQQGFJKYGEQQ-UHFFFAOYSA-N 3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)benzonitrile Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1C#N CUTQQGFJKYGEQQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000034353 G alpha subunit Human genes 0.000 description 2
- 108091006099 G alpha subunit Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- QDUXRJZDYUJECT-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CN Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CN QDUXRJZDYUJECT-LREBCSMRSA-N 0.000 description 2
- NLPQEJNUWGRTSY-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNCC1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNCC1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 NLPQEJNUWGRTSY-LREBCSMRSA-N 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- RAAPEGKFTBOHHI-UHFFFAOYSA-N [1-[2-[(dimethylamino)methyl]-6-fluorophenyl]-3-methylpyrazol-4-yl]methanol Chemical compound CN(C)CC1=CC=CC(F)=C1N1N=C(C)C(CO)=C1 RAAPEGKFTBOHHI-UHFFFAOYSA-N 0.000 description 2
- KNYSGYBGOSDIBY-UHFFFAOYSA-N [1-[2-[(dimethylamino)methyl]phenyl]-3-methylpyrazol-4-yl]methanol Chemical compound CN(C)CC1=CC=CC=C1N1N=C(C)C(CO)=C1 KNYSGYBGOSDIBY-UHFFFAOYSA-N 0.000 description 2
- QJAZLUHYRQDAOM-UHFFFAOYSA-N [1-[2-fluoro-6-(methoxymethyl)phenyl]-3-methylpyrazol-4-yl]methanol Chemical compound COCC1=CC=CC(F)=C1N1N=C(C)C(CO)=C1 QJAZLUHYRQDAOM-UHFFFAOYSA-N 0.000 description 2
- RTDIRRREGJOPPN-UHFFFAOYSA-N [1-[2-fluoro-6-(morpholin-4-ylmethyl)phenyl]-3-methylpyrazol-4-yl]methanol Chemical compound C1=C(CO)C(C)=NN1C1=C(F)C=CC=C1CN1CCOCC1 RTDIRRREGJOPPN-UHFFFAOYSA-N 0.000 description 2
- IDMYWOHNBHPTII-LREBCSMRSA-N [2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methanol (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CO IDMYWOHNBHPTII-LREBCSMRSA-N 0.000 description 2
- KGFCOCLGHPXYIN-UHFFFAOYSA-N [3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)phenyl]methyl n-methylcarbamate Chemical compound CNC(=O)OCC1=CC=CC(F)=C1N1N=C(C)C(C=O)=C1 KGFCOCLGHPXYIN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- QDGUVDNRFUGWMZ-UHFFFAOYSA-N ethyl 1-(2-fluoro-6-formylphenyl)-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1C=O QDGUVDNRFUGWMZ-UHFFFAOYSA-N 0.000 description 2
- KUVYKBQZNYDRFB-UHFFFAOYSA-N ethyl 1-(2-fluorophenyl)-4-formylpyrazole-3-carboxylate Chemical compound C1=C(C=O)C(C(=O)OCC)=NN1C1=CC=CC=C1F KUVYKBQZNYDRFB-UHFFFAOYSA-N 0.000 description 2
- PBLQFMYMFSDTMZ-UHFFFAOYSA-N ethyl 1-[2-[(dimethylamino)methyl]-6-fluorophenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1CN(C)C PBLQFMYMFSDTMZ-UHFFFAOYSA-N 0.000 description 2
- VCYOAILWAXAAQZ-UHFFFAOYSA-N ethyl 1-[2-[[cyclopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]-6-fluorophenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1CN(C(=O)OC(C)(C)C)C1CC1 VCYOAILWAXAAQZ-UHFFFAOYSA-N 0.000 description 2
- SFROKUQQAIJMSH-UHFFFAOYSA-N ethyl 1-[2-fluoro-6-(1-methylimidazol-2-yl)phenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1C1=NC=CN1C SFROKUQQAIJMSH-UHFFFAOYSA-N 0.000 description 2
- HHYVTIKYZUMDIL-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1C HHYVTIKYZUMDIL-UHFFFAOYSA-N 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 108010006205 fluorescein isothiocyanate bovine serum albumin Proteins 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VFTZKSMAJVLWOV-UHFFFAOYSA-N methyl 1h-pyrazole-4-carboxylate Chemical compound COC(=O)C=1C=NNC=1 VFTZKSMAJVLWOV-UHFFFAOYSA-N 0.000 description 2
- PABOEHCUBDHETJ-UHFFFAOYSA-N methyl 2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorobenzoate Chemical compound COC(=O)C1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 PABOEHCUBDHETJ-UHFFFAOYSA-N 0.000 description 2
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 2
- RFPMTAUCGYUYFU-UHFFFAOYSA-N methyl n-[3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)phenyl]-n-methylcarbamate Chemical compound COC(=O)N(C)C1=CC=CC(F)=C1N1N=C(C)C(C=O)=C1 RFPMTAUCGYUYFU-UHFFFAOYSA-N 0.000 description 2
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000002764 nociceptin receptor antagonist Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000004305 normal phase HPLC Methods 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- DWYGLHSLUMTSPC-UHFFFAOYSA-N spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine] Chemical group C1CNCCC21C(SC=C1)=C1CCO2 DWYGLHSLUMTSPC-UHFFFAOYSA-N 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QMKKTVXAYUUJAA-UHFFFAOYSA-N tert-butyl 1-(2-fluorophenyl)-3-methylpyrazole-4-carboxylate Chemical compound C1=C(C(=O)OC(C)(C)C)C(C)=NN1C1=CC=CC=C1F QMKKTVXAYUUJAA-UHFFFAOYSA-N 0.000 description 2
- RYXFGQMQOJPDSA-UHFFFAOYSA-N tert-butyl 2'-bromo-4'-oxospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(SC(Br)=C1)=C1C(=O)CO2 RYXFGQMQOJPDSA-UHFFFAOYSA-N 0.000 description 2
- WWOBSAGUWADOLZ-UHFFFAOYSA-N tert-butyl 2'-chloro-4'-oxospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(SC(Cl)=C1)=C1C(=O)CO2 WWOBSAGUWADOLZ-UHFFFAOYSA-N 0.000 description 2
- RYBFPZPUUXTKCZ-UHFFFAOYSA-N tert-butyl 2-bromo-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(SC(Br)=C1)=C1C(F)(F)CO2 RYBFPZPUUXTKCZ-UHFFFAOYSA-N 0.000 description 2
- WNXSDRJELBFVEP-UHFFFAOYSA-N tert-butyl 3-(bromomethyl)-1-(2-fluorophenyl)pyrazole-4-carboxylate Chemical compound N1=C(CBr)C(C(=O)OC(C)(C)C)=CN1C1=CC=CC=C1F WNXSDRJELBFVEP-UHFFFAOYSA-N 0.000 description 2
- IFDITPFMGGLVMB-UHFFFAOYSA-N tert-butyl spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(SC=C1)=C1CCO2 IFDITPFMGGLVMB-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RSOSGLCEIHAGQV-UHFFFAOYSA-N (2,6-difluorophenyl)hydrazine;hydrochloride Chemical compound [Cl-].[NH3+]NC1=C(F)C=CC=C1F RSOSGLCEIHAGQV-UHFFFAOYSA-N 0.000 description 1
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- VFZYLSYYMHFPSY-UHFFFAOYSA-N (2-fluoroanilino)azanium;chloride Chemical compound Cl.NNC1=CC=CC=C1F VFZYLSYYMHFPSY-UHFFFAOYSA-N 0.000 description 1
- PENWGQNPFRRVQI-UHFFFAOYSA-N (2-fluorophenyl)hydrazine Chemical compound NNC1=CC=CC=C1F PENWGQNPFRRVQI-UHFFFAOYSA-N 0.000 description 1
- XBJLPMDTGMZBLV-UHFFFAOYSA-N 1'-tert-butyl-2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1CN(C(C)(C)C)CCC21C(SC(Cl)=C1)=C1CCO2 XBJLPMDTGMZBLV-UHFFFAOYSA-N 0.000 description 1
- LGZDNJBUAAXEMN-UHFFFAOYSA-N 1,2,2,3-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1CCC[N+](C)([O-])C1(C)C LGZDNJBUAAXEMN-UHFFFAOYSA-N 0.000 description 1
- IXIJRPBFPLESEI-UHFFFAOYSA-N 1,2-difluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1F IXIJRPBFPLESEI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- MTMIJRZSNIOZCJ-UHFFFAOYSA-N 1-(2-amino-6-fluorophenyl)-3-methylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(C)=NN1C1=C(N)C=CC=C1F MTMIJRZSNIOZCJ-UHFFFAOYSA-N 0.000 description 1
- LVNWNMSSBXTFMW-UHFFFAOYSA-N 1-(2-fluoro-6-nitrophenyl)-3-methylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1[N+]([O-])=O LVNWNMSSBXTFMW-UHFFFAOYSA-N 0.000 description 1
- JQFRODVWEXBLAW-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-(methoxymethyl)pyrazole Chemical compound N1=C(COC)C=CN1C1=CC=CC=C1F JQFRODVWEXBLAW-UHFFFAOYSA-N 0.000 description 1
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- CGFFSPCPFKKEKA-UHFFFAOYSA-N 1-[2-[(dimethylamino)methyl]-6-fluorophenyl]-3-methylpyrazole-4-carbaldehyde Chemical compound CN(C)CC1=CC=CC(F)=C1N1N=C(C)C(C=O)=C1 CGFFSPCPFKKEKA-UHFFFAOYSA-N 0.000 description 1
- KADYOAUBYIPPDU-LREBCSMRSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]-N,N-dimethylcyclopropan-1-amine (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C=1C=CC(F)=C(N2N=C(C)C(CN3CCC4(CC3)C=3SC(Cl)=CC=3C(F)(F)CO4)=C2)C=1C1(N(C)C)CC1 KADYOAUBYIPPDU-LREBCSMRSA-N 0.000 description 1
- VWYMLYKPQPUGKY-LREBCSMRSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]cyclopropan-1-amine (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C1(N)CC1 VWYMLYKPQPUGKY-LREBCSMRSA-N 0.000 description 1
- APQWZBLQMWSUIK-LREBCSMRSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-methoxyphenyl]-N-methylmethanamine (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNCC1=CC=CC(OC)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 APQWZBLQMWSUIK-LREBCSMRSA-N 0.000 description 1
- DJNPTQOCOKRPIG-UHFFFAOYSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]-n,n-dimethylcyclopropan-1-amine Chemical compound C=1C=CC(F)=C(N2N=C(C)C(CN3CCC4(CC3)C=3SC(Cl)=CC=3C(F)(F)CO4)=C2)C=1C1(N(C)C)CC1 DJNPTQOCOKRPIG-UHFFFAOYSA-N 0.000 description 1
- PUNBGDJMUIOGAT-UHFFFAOYSA-N 1-[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]-n-(2-methoxyethyl)methanimine Chemical compound COCCN=CC1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 PUNBGDJMUIOGAT-UHFFFAOYSA-N 0.000 description 1
- MKBHCNUPBQLSKM-UHFFFAOYSA-N 1-[2-chloro-6-[(dimethylamino)methyl]phenyl]-3-methylpyrazole-4-carbaldehyde Chemical compound CN(C)CC1=CC=CC(Cl)=C1N1N=C(C)C(C=O)=C1 MKBHCNUPBQLSKM-UHFFFAOYSA-N 0.000 description 1
- CPTMVKLYWHEOMG-UHFFFAOYSA-N 1-fluoro-2-iodo-3-methoxybenzene Chemical compound COC1=CC=CC(F)=C1I CPTMVKLYWHEOMG-UHFFFAOYSA-N 0.000 description 1
- TYHUGKGZNOULKD-UHFFFAOYSA-N 1-fluoro-2-iodobenzene Chemical compound FC1=CC=CC=C1I TYHUGKGZNOULKD-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- RINOYHWVBUKAQE-UHFFFAOYSA-N 1-iodo-2-methylbenzene Chemical compound CC1=CC=CC=C1I RINOYHWVBUKAQE-UHFFFAOYSA-N 0.000 description 1
- ANFXTILBDGTSEG-UHFFFAOYSA-N 1-methyl-4,5-dihydroimidazole Chemical compound CN1CCN=C1 ANFXTILBDGTSEG-UHFFFAOYSA-N 0.000 description 1
- HIYDOOYADAKGDQ-UHFFFAOYSA-N 2,3-difluoro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(F)=C1F HIYDOOYADAKGDQ-UHFFFAOYSA-N 0.000 description 1
- DDAINDMVKSETGF-UHFFFAOYSA-N 2,3-difluorobenzamide Chemical compound NC(=O)C1=CC=CC(F)=C1F DDAINDMVKSETGF-UHFFFAOYSA-N 0.000 description 1
- BUJVOLSOLNFQJT-UHFFFAOYSA-N 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoic acid Chemical compound C1CC2(C=3SC(F)=CC=3CCO2)CCN1CC(C(=O)O)CC1=CC=CC=C1F BUJVOLSOLNFQJT-UHFFFAOYSA-N 0.000 description 1
- ZAOOBQSQJCZQRU-UHFFFAOYSA-N 2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluoroaniline Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(N)C=CC=C1F ZAOOBQSQJCZQRU-UHFFFAOYSA-N 0.000 description 1
- UAJJEQLXMDAMCJ-UHFFFAOYSA-N 2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorobenzaldehyde Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C=O UAJJEQLXMDAMCJ-UHFFFAOYSA-N 0.000 description 1
- DNFFHKWWGDTOTR-UHFFFAOYSA-N 2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorobenzamide Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C(N)=O DNFFHKWWGDTOTR-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- VUOLAGNWVDFGEX-UHFFFAOYSA-N 2-[[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 VUOLAGNWVDFGEX-UHFFFAOYSA-N 0.000 description 1
- HJAQEBQKDAJQRY-UHFFFAOYSA-N 2-[[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methylamino]ethanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CNCCO HJAQEBQKDAJQRY-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HRZTZLCMURHWFY-UHFFFAOYSA-N 2-bromo-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1Br HRZTZLCMURHWFY-UHFFFAOYSA-N 0.000 description 1
- XZPLGWDRMOMJEQ-UHFFFAOYSA-N 2-chloro-1'-[[1-(2,6-dimethylphenyl)-3-methylpyrazol-4-yl]methyl]-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(C)C=CC=C1C XZPLGWDRMOMJEQ-UHFFFAOYSA-N 0.000 description 1
- ZIXOGFZZXPZZCE-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-(2-fluoro-6-methoxyphenyl)-3-methylpyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound COC1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 ZIXOGFZZXPZZCE-UHFFFAOYSA-N 0.000 description 1
- QSIXHJSIUCACOY-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-(2-fluorophenyl)-3-(methoxymethyl)pyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(COC)=NN1C1=CC=CC=C1F QSIXHJSIUCACOY-UHFFFAOYSA-N 0.000 description 1
- XXTAOIPDMBHKNU-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-[2-fluoro-6-(1-methylimidazol-2-yl)phenyl]-3-methylpyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C1=NC=CN1C XXTAOIPDMBHKNU-UHFFFAOYSA-N 0.000 description 1
- NDESORITPQFVQC-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-[2-fluoro-6-(1h-1,2,4-triazol-5-yl)phenyl]-3-methylpyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1C=1N=CNN=1 NDESORITPQFVQC-UHFFFAOYSA-N 0.000 description 1
- CYXMKMNJAYLVNQ-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[1-[2-fluoro-6-(isoindol-2-ylmethyl)phenyl]-3-methylpyrazol-4-yl]methyl]spiro[5H-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound ClC1=CC2=C(C3(OCC2(F)F)CCN(CC3)CC=3C(=NN(C3)C3=C(CN2C=C4C=CC=CC4=C2)C=CC=C3F)C)S1 CYXMKMNJAYLVNQ-UHFFFAOYSA-N 0.000 description 1
- LFJUFKLBEDBJPR-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[3-methyl-1-(2-methylphenyl)pyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=CC=CC=C1C LFJUFKLBEDBJPR-UHFFFAOYSA-N 0.000 description 1
- LIHCOUDNHILORI-UHFFFAOYSA-N 2-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1F LIHCOUDNHILORI-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LKKWNBWRPDKMIB-UHFFFAOYSA-N 3-chloro-1-phenylpiperazine Chemical compound C1CNC(Cl)CN1C1=CC=CC=C1 LKKWNBWRPDKMIB-UHFFFAOYSA-N 0.000 description 1
- LYQBOHWMBZPNJR-UHFFFAOYSA-N 3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)benzamide Chemical compound C1=C(C=O)C(C)=NN1C1=C(F)C=CC=C1C(N)=O LYQBOHWMBZPNJR-UHFFFAOYSA-N 0.000 description 1
- LQUHHIYASKFFMJ-UHFFFAOYSA-N 3-methyl-1h-pyrazole Chemical compound CC=1C=[C]NN=1 LQUHHIYASKFFMJ-UHFFFAOYSA-N 0.000 description 1
- IGJYNRJBRWKKKT-UHFFFAOYSA-N 4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound FC1(C2=C(SC=C2)C2(CCNCC2)OC1)F IGJYNRJBRWKKKT-UHFFFAOYSA-N 0.000 description 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- VKQDGZFAIBIEAF-UHFFFAOYSA-N 7h-thieno[2,3-c]pyran Chemical compound C1OC=CC2=C1SC=C2 VKQDGZFAIBIEAF-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101000742062 Bos taurus Protein phosphatase 1G Proteins 0.000 description 1
- NUSWEVIJSVOOKE-UHFFFAOYSA-N BrN1C(CCC1=O)=O.BrC1=CC2=C(C3(OCC2O)CCN(CC3)C(=O)OC(C)(C)C)S1 Chemical compound BrN1C(CCC1=O)=O.BrC1=CC2=C(C3(OCC2O)CCN(CC3)C(=O)OC(C)(C)C)S1 NUSWEVIJSVOOKE-UHFFFAOYSA-N 0.000 description 1
- AOVPDEJMILLEGE-UHFFFAOYSA-N C(C)(C)(C)OC(N(CC1=C(C(=CC=C1)F)N1N=C(C(=C1)C=O)C)CCC)=O Chemical compound C(C)(C)(C)OC(N(CC1=C(C(=CC=C1)F)N1N=C(C(=C1)C=O)C)CCC)=O AOVPDEJMILLEGE-UHFFFAOYSA-N 0.000 description 1
- UWHXAPBHXIDOOL-UHFFFAOYSA-N C(C)C=1C(=NN(C1)C1=C(C=CC=C1F)CN(C)C)C Chemical compound C(C)C=1C(=NN(C1)C1=C(C=CC=C1F)CN(C)C)C UWHXAPBHXIDOOL-UHFFFAOYSA-N 0.000 description 1
- BPTKOQQLAYLINS-UHFFFAOYSA-N C(C)OC(=O)C=1C(=NNC1)C.C(C)OC(=O)C=1C(=NN(C1)C1=C(C=CC=C1F)C#N)C Chemical compound C(C)OC(=O)C=1C(=NNC1)C.C(C)OC(=O)C=1C(=NN(C1)C1=C(C=CC=C1F)C#N)C BPTKOQQLAYLINS-UHFFFAOYSA-N 0.000 description 1
- LEIFQUFRUJIIMU-UHFFFAOYSA-N CC(C)(C)C(CC1)CCC1(C(S1)=C2C=C1Br)OCC2O Chemical compound CC(C)(C)C(CC1)CCC1(C(S1)=C2C=C1Br)OCC2O LEIFQUFRUJIIMU-UHFFFAOYSA-N 0.000 description 1
- PSCHLOLUKMZAOZ-UAXCXUHQSA-N CC/C(/F)=C(\C)/N(C)/N=C/C(CO)C(CN(CCCC(S1)=C(CF)CC1Cl)CCOCCF)=C Chemical compound CC/C(/F)=C(\C)/N(C)/N=C/C(CO)C(CN(CCCC(S1)=C(CF)CC1Cl)CCOCCF)=C PSCHLOLUKMZAOZ-UAXCXUHQSA-N 0.000 description 1
- MVBNDLISKKIJLY-UVKVRZDQSA-N CCOCCN(CCc([s]1)c(CF)cc1Cl)CC1=CN(C/C(/C)=C(\C2(C)CC2)/C=C\C)N[C@@H]1C Chemical compound CCOCCN(CCc([s]1)c(CF)cc1Cl)CC1=CN(C/C(/C)=C(\C2(C)CC2)/C=C\C)N[C@@H]1C MVBNDLISKKIJLY-UVKVRZDQSA-N 0.000 description 1
- PWIPMOQZARUPEB-UHFFFAOYSA-N CN(C=O)C.FC1=C(C(=CC=C1)F)N1N=C(C(=C1)C=O)C(=O)OCC Chemical compound CN(C=O)C.FC1=C(C(=CC=C1)F)N1N=C(C(=C1)C=O)C(=O)OCC PWIPMOQZARUPEB-UHFFFAOYSA-N 0.000 description 1
- QALAUVYSFDOBOY-SEJCPJDGSA-N C[C@@H](/C=C\C=C(/CN1N(C)C(C)(C)C([I]=O)=C1)\F)N(C)C(OC)=O Chemical compound C[C@@H](/C=C\C=C(/CN1N(C)C(C)(C)C([I]=O)=C1)\F)N(C)C(OC)=O QALAUVYSFDOBOY-SEJCPJDGSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- PWCFERZVWZKILN-UHFFFAOYSA-N Cc(c(CN(CCCc([s]1)c2cc1Cl)CCCOCC2(F)F)c1)n[n]1-c(c(C1(CC1)N)ccc1)c1F Chemical compound Cc(c(CN(CCCc([s]1)c2cc1Cl)CCCOCC2(F)F)c1)n[n]1-c(c(C1(CC1)N)ccc1)c1F PWCFERZVWZKILN-UHFFFAOYSA-N 0.000 description 1
- JOURZDBVAJCUPT-UHFFFAOYSA-N Cc1c[n](-c(c(COC)ccc2)c2F)nc1C Chemical compound Cc1c[n](-c(c(COC)ccc2)c2F)nc1C JOURZDBVAJCUPT-UHFFFAOYSA-N 0.000 description 1
- WZUJQIJNZHILFO-UHFFFAOYSA-N ClCCCl.N1N=C(C=C1)C(=O)O Chemical compound ClCCCl.N1N=C(C=C1)C(=O)O WZUJQIJNZHILFO-UHFFFAOYSA-N 0.000 description 1
- ZABTWYBROCHNQS-UHFFFAOYSA-N ClCCl.FC1=C(C(=CC=C1)COC(NC)=O)N1N=C(C(=C1)C(=O)OCC)C Chemical compound ClCCl.FC1=C(C(=CC=C1)COC(NC)=O)N1N=C(C(=C1)C(=O)OCC)C ZABTWYBROCHNQS-UHFFFAOYSA-N 0.000 description 1
- YCKRCWGTORZOGJ-UHFFFAOYSA-N ClCCl.FC1=C(C=CC=C1)N1N=C(C(=C1)C=O)COC Chemical compound ClCCl.FC1=C(C=CC=C1)N1N=C(C(=C1)C=O)COC YCKRCWGTORZOGJ-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DMKSMSOWRULVDY-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC1=C(C=CC=C1)CC(C(=O)O)CN1CCC2(CC1)OCCC1=C2SC(=C1)F Chemical compound FC(C(=O)O)(F)F.FC1=C(C=CC=C1)CC(C(=O)O)CN1CCC2(CC1)OCCC1=C2SC(=C1)F DMKSMSOWRULVDY-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- ZHZOPZLZYXZYSR-LREBCSMRSA-N N-[[2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methyl]-N-methylacetamide (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)N(C)CC1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 ZHZOPZLZYXZYSR-LREBCSMRSA-N 0.000 description 1
- WBCYEAMAUYXPLC-LREBCSMRSA-N N-[[2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methyl]cyclopropanamine (2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CNC1CC1 WBCYEAMAUYXPLC-LREBCSMRSA-N 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- YPSJPCUUBCZJQD-OLXYHTOASA-N O1CCCC1.C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.CO Chemical compound O1CCCC1.C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.CO YPSJPCUUBCZJQD-OLXYHTOASA-N 0.000 description 1
- MKDJGEVQNAXLRM-UHFFFAOYSA-N O1CCCC1.ClC1=CC2=C(S1)C1(CCN(CC1)CC=1C(=NN(C1)C1=C(C=CC=C1)F)CO)OCC2(F)F Chemical compound O1CCCC1.ClC1=CC2=C(S1)C1(CCN(CC1)CC=1C(=NN(C1)C1=C(C=CC=C1)F)CO)OCC2(F)F MKDJGEVQNAXLRM-UHFFFAOYSA-N 0.000 description 1
- IGLALAUKGVTKLU-UHFFFAOYSA-N O1CCCC1.FC1=C(C=CC=C1)N1N=C(C(=C1)CO)COC Chemical compound O1CCCC1.FC1=C(C=CC=C1)N1N=C(C(=C1)CO)COC IGLALAUKGVTKLU-UHFFFAOYSA-N 0.000 description 1
- GYEWDIPSOZLSCO-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CN1CCCC1 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CN1CCCC1 GYEWDIPSOZLSCO-LREBCSMRSA-N 0.000 description 1
- CXIOABSQSYXLCY-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1N1C=CN=C1 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1N1C=CN=C1 CXIOABSQSYXLCY-LREBCSMRSA-N 0.000 description 1
- SDLFCDVIVPYIJO-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1N1C=CN=C1C Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1N1C=CN=C1C SDLFCDVIVPYIJO-LREBCSMRSA-N 0.000 description 1
- PXLPJRKYJTUAGU-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=CC=CC=C1Cl Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=CC=CC=C1Cl PXLPJRKYJTUAGU-LREBCSMRSA-N 0.000 description 1
- POWBAWLTAOXHBG-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=CC=CC=C1F Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=CC=CC=C1F POWBAWLTAOXHBG-LREBCSMRSA-N 0.000 description 1
- SPTSHHMVMFIFRZ-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(COC)=NN1C1=CC=CC=C1F Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(COC)=NN1C1=CC=CC=C1F SPTSHHMVMFIFRZ-LREBCSMRSA-N 0.000 description 1
- RLFLBNZJFJOODD-LREBCSMRSA-N OC(=O)[C@H](O)[C@@H](O)C(O)=O.COC(=O)N(C)C1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COC(=O)N(C)C1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 RLFLBNZJFJOODD-LREBCSMRSA-N 0.000 description 1
- FKFBSAKOTQJVDE-UHFFFAOYSA-N OC(C(C(O)=O)O)C(O)=O.OC(C(C(O)=O)O)C(O)=O.OC(C(C(O)=O)O)C(O)=O.N.N Chemical compound OC(C(C(O)=O)O)C(O)=O.OC(C(C(O)=O)O)C(O)=O.OC(C(C(O)=O)O)C(O)=O.N.N FKFBSAKOTQJVDE-UHFFFAOYSA-N 0.000 description 1
- RFZCIGQKJQDUBF-UHFFFAOYSA-N P(=O)(Cl)(Cl)Cl.FC1=C(C(=CC=C1)F)N1N=C(C(=C1)C=O)C Chemical compound P(=O)(Cl)(Cl)Cl.FC1=C(C(=CC=C1)F)N1N=C(C(=C1)C=O)C RFZCIGQKJQDUBF-UHFFFAOYSA-N 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HVELEPKPBXUIAZ-UHFFFAOYSA-N [1-(2-fluorophenyl)-3-(methoxymethyl)pyrazol-4-yl]methanol Chemical compound C1=C(CO)C(COC)=NN1C1=CC=CC=C1F HVELEPKPBXUIAZ-UHFFFAOYSA-N 0.000 description 1
- LLTNWNDGIRFQJG-UHFFFAOYSA-N [1-[2-fluoro-6-(1-methylimidazol-2-yl)phenyl]-3-methylpyrazol-4-yl]methanol Chemical compound C1=C(CO)C(C)=NN1C1=C(F)C=CC=C1C1=NC=CN1C LLTNWNDGIRFQJG-UHFFFAOYSA-N 0.000 description 1
- LXGQHDUCNDGTDB-PAMNCVQHSA-N [2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;[2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11, Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)CC2O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)CC2O LXGQHDUCNDGTDB-PAMNCVQHSA-N 0.000 description 1
- GBNUMIAMFXWHBQ-UHFFFAOYSA-N [2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-cyclopropylphenyl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(CO)C=CC=C1C1CC1 GBNUMIAMFXWHBQ-UHFFFAOYSA-N 0.000 description 1
- SDLPQWDVSADQSC-UHFFFAOYSA-N [2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methanamine Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CN SDLPQWDVSADQSC-UHFFFAOYSA-N 0.000 description 1
- HMSMKAABBGJSHD-UHFFFAOYSA-N [2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=C(F)C=CC=C1CO HMSMKAABBGJSHD-UHFFFAOYSA-N 0.000 description 1
- YMSFOGHSAYOHKU-UHFFFAOYSA-N [3-fluoro-2-[4-(hydroxymethyl)-3-methylpyrazol-1-yl]phenyl]methyl n-methylcarbamate Chemical compound CNC(=O)OCC1=CC=CC(F)=C1N1N=C(C)C(CO)=C1 YMSFOGHSAYOHKU-UHFFFAOYSA-N 0.000 description 1
- DHSXGJLFQNUKJV-UHFFFAOYSA-N [4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-1-(2,6-difluorophenyl)pyrazol-3-yl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(CO)=NN1C1=C(F)C=CC=C1F DHSXGJLFQNUKJV-UHFFFAOYSA-N 0.000 description 1
- JJWDJWQBHRUEIN-UHFFFAOYSA-N [4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-1-(2-fluorophenyl)pyrazol-3-yl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(CO)=NN1C1=CC=CC=C1F JJWDJWQBHRUEIN-UHFFFAOYSA-N 0.000 description 1
- FULNXPMHFMEUPB-UHFFFAOYSA-M [Br-].[K+].BrC1=CC2=C(S1)C1(CCN(CC1)C(=O)OC(C)(C)C)OCC2=O Chemical compound [Br-].[K+].BrC1=CC2=C(S1)C1(CCN(CC1)C(=O)OC(C)(C)C)OCC2=O FULNXPMHFMEUPB-UHFFFAOYSA-M 0.000 description 1
- SPAVAFPDOPVJQU-UHFFFAOYSA-N [O-2].[Mn+4].ClC1=CC2=C(S1)C1(CCN(CC1)CC=1C(=NN(C1)C1=C(C=O)C=CC=C1F)C)OCC2(F)F.[O-2] Chemical compound [O-2].[Mn+4].ClC1=CC2=C(S1)C1(CCN(CC1)CC=1C(=NN(C1)C1=C(C=O)C=CC=C1F)C)OCC2(F)F.[O-2] SPAVAFPDOPVJQU-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical group OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- LILMZOXHBBCGDY-UHFFFAOYSA-M disodium hydrogen carbonate hypochlorite Chemical class [Na+].[Na+].Cl[O-].OC([O-])=O LILMZOXHBBCGDY-UHFFFAOYSA-M 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- YEFNQGRXPXYCPT-UHFFFAOYSA-N ethyl 1-(2,6-difluorophenyl)-4-formylpyrazole-3-carboxylate Chemical compound C1=C(C=O)C(C(=O)OCC)=NN1C1=C(F)C=CC=C1F YEFNQGRXPXYCPT-UHFFFAOYSA-N 0.000 description 1
- CBUBZKKNUVCPRV-UHFFFAOYSA-N ethyl 1-(2-chloro-6-formylphenyl)-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(Cl)C=CC=C1C=O CBUBZKKNUVCPRV-UHFFFAOYSA-N 0.000 description 1
- KJCPQVZUYOHKNC-UHFFFAOYSA-N ethyl 1-(2-cyano-6-fluorophenyl)-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1C#N KJCPQVZUYOHKNC-UHFFFAOYSA-N 0.000 description 1
- RLFATVDJKKNOSY-UHFFFAOYSA-N ethyl 1-[2-[(cyclopropylamino)methyl]-6-fluorophenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1CNC1CC1 RLFATVDJKKNOSY-UHFFFAOYSA-N 0.000 description 1
- MCMQNCXEXQQEQC-UHFFFAOYSA-N ethyl 1-[2-[(dimethylamino)methyl]-6-fluorophenyl]-5-ethyl-3-methylpyrazole-4-carboxylate Chemical compound CCC1=C(C(=O)OCC)C(C)=NN1C1=C(F)C=CC=C1CN(C)C MCMQNCXEXQQEQC-UHFFFAOYSA-N 0.000 description 1
- KJGKMGZKZXTBGB-UHFFFAOYSA-N ethyl 1-[2-fluoro-6-(1-methyl-4,5-dihydroimidazol-2-yl)phenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1C1=NCCN1C KJGKMGZKZXTBGB-UHFFFAOYSA-N 0.000 description 1
- ORPWOVUHFGZFRO-UHFFFAOYSA-N ethyl 1-[2-fluoro-6-(hydroxymethyl)phenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1CO ORPWOVUHFGZFRO-UHFFFAOYSA-N 0.000 description 1
- RAZBGYBESVKZGE-UHFFFAOYSA-N ethyl 1-[2-fluoro-6-(methoxymethyl)phenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1COC RAZBGYBESVKZGE-UHFFFAOYSA-N 0.000 description 1
- YVVQKYKKTOUTCD-UHFFFAOYSA-N ethyl 1-[2-fluoro-6-(morpholin-4-ylmethyl)phenyl]-3-methylpyrazole-4-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=CN1C1=C(F)C=CC=C1CN1CCOCC1 YVVQKYKKTOUTCD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003031 feeding effect Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- BNHFWQQYLUPDOG-UHFFFAOYSA-N lithium;1,2,2,3-tetramethylpiperidine Chemical compound [Li].CC1CCCN(C)C1(C)C BNHFWQQYLUPDOG-UHFFFAOYSA-N 0.000 description 1
- JCIVHYBIFRUGKO-UHFFFAOYSA-N lithium;2,2,6,6-tetramethylpiperidine Chemical compound [Li].CC1(C)CCCC(C)(C)N1 JCIVHYBIFRUGKO-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
- FMTHVBOWAILEFZ-UHFFFAOYSA-N methyl 2,3-difluorobenzoate Chemical compound COC(=O)C1=CC=CC(F)=C1F FMTHVBOWAILEFZ-UHFFFAOYSA-N 0.000 description 1
- RFYUVODFBYCKNG-UHFFFAOYSA-N methyl 2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-cyclopropylbenzoate Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C=1C(C(=O)OC)=CC=CC=1C1CC1 RFYUVODFBYCKNG-UHFFFAOYSA-N 0.000 description 1
- GHWNTMPNVGYTPH-UHFFFAOYSA-N methyl 3-bromo-2-(4-formyl-3-methylpyrazol-1-yl)benzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1N1N=C(C)C(C=O)=C1 GHWNTMPNVGYTPH-UHFFFAOYSA-N 0.000 description 1
- SKOIAVNDNKLDAY-UHFFFAOYSA-N methyl 3-cyclopropyl-2-(4-formyl-3-methylpyrazol-1-yl)benzoate Chemical compound C1=C(C=O)C(C)=NN1C=1C(C(=O)OC)=CC=CC=1C1CC1 SKOIAVNDNKLDAY-UHFFFAOYSA-N 0.000 description 1
- QXIVLPBRLKGDIC-UHFFFAOYSA-N methyl 3-fluoro-2-(4-formyl-3-methylpyrazol-1-yl)benzoate Chemical compound COC(=O)C1=CC=CC(F)=C1N1N=C(C)C(C=O)=C1 QXIVLPBRLKGDIC-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- GSOPPOMZKFVQDJ-UHFFFAOYSA-N methyl n-[2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]-3-fluorophenyl]-n-methylcarbamate Chemical compound COC(=O)N(C)C1=CC=CC(F)=C1N1N=C(C)C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)=C1 GSOPPOMZKFVQDJ-UHFFFAOYSA-N 0.000 description 1
- NYXHSRNBKJIQQG-UHFFFAOYSA-N methyl n-methylcarbamate Chemical compound CNC(=O)OC NYXHSRNBKJIQQG-UHFFFAOYSA-N 0.000 description 1
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- IPIPITPLRMYYCW-UHFFFAOYSA-N n-propyl-n-(trifluoro-$l^{4}-sulfanyl)propan-1-amine Chemical compound CCCN(S(F)(F)F)CCC IPIPITPLRMYYCW-UHFFFAOYSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000002485 serotonin 2C agonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- HCNSVZAEDYDEFK-UHFFFAOYSA-N spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidin-1-ium];2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1C[NH2+]CCC21C(SC=C1)=C1CCO2 HCNSVZAEDYDEFK-UHFFFAOYSA-N 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- DUAYKFWVNCCEHS-UHFFFAOYSA-N tert-butyl 2,4,4-trifluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(SC(F)=C1)=C1C(F)(F)CO2 DUAYKFWVNCCEHS-UHFFFAOYSA-N 0.000 description 1
- ZGOXJYHSQQTBNK-UHFFFAOYSA-N tert-butyl 2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-carboxylate oxolane Chemical compound O1CCCC1.ClC1=CC2=C(C3(OCC2(F)F)CCN(CC3)C(=O)OC(C)(C)C)S1 ZGOXJYHSQQTBNK-UHFFFAOYSA-N 0.000 description 1
- PEWMVDIBIRMSAC-UHFFFAOYSA-N tert-butyl 2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(SC(Cl)=C1)=C1CCO2 PEWMVDIBIRMSAC-UHFFFAOYSA-N 0.000 description 1
- PIZRHGWZUVTVQJ-UHFFFAOYSA-N tert-butyl 2-fluoroacetate Chemical compound CC(C)(C)OC(=O)CF PIZRHGWZUVTVQJ-UHFFFAOYSA-N 0.000 description 1
- UIYDGRPWECFCLH-UHFFFAOYSA-N tert-butyl 2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-carboxylate 2,2,6,6-tetramethylpiperidine Chemical compound CC1(NC(CCC1)(C)C)C.FC1=CC2=C(C3(OCC2)CCN(CC3)C(=O)OC(C)(C)C)S1 UIYDGRPWECFCLH-UHFFFAOYSA-N 0.000 description 1
- JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- OTFQSEYOEXRUEB-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[3-fluoro-2-[4-(hydroxymethyl)-3-methylpyrazol-1-yl]phenyl]methyl]carbamate Chemical compound C1=C(CO)C(C)=NN1C1=C(F)C=CC=C1CN(C(=O)OC(C)(C)C)C1CC1 OTFQSEYOEXRUEB-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382245 | 2009-11-16 | ||
| EP09382245.0 | 2009-11-16 | ||
| US29862810P | 2010-01-27 | 2010-01-27 | |
| US61/298,628 | 2010-01-27 | ||
| PCT/US2010/056449 WO2011060217A1 (en) | 2009-11-16 | 2010-11-12 | Spiropiperidine compounds as orl-1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510870A JP2013510870A (ja) | 2013-03-28 |
| JP2013510870A5 JP2013510870A5 (enExample) | 2013-11-21 |
| JP5723381B2 true JP5723381B2 (ja) | 2015-05-27 |
Family
ID=41800752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538997A Active JP5723381B2 (ja) | 2009-11-16 | 2010-11-12 | Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120214784A1 (enExample) |
| EP (1) | EP2501704B1 (enExample) |
| JP (1) | JP5723381B2 (enExample) |
| KR (1) | KR101368130B1 (enExample) |
| CN (1) | CN102666550B (enExample) |
| AU (1) | AU2010319400B2 (enExample) |
| BR (1) | BR112012011710A2 (enExample) |
| CA (1) | CA2781041C (enExample) |
| DK (1) | DK2501704T3 (enExample) |
| EA (1) | EA020391B1 (enExample) |
| ES (1) | ES2436241T3 (enExample) |
| HR (1) | HRP20130969T1 (enExample) |
| MX (1) | MX2012005690A (enExample) |
| PL (1) | PL2501704T3 (enExample) |
| PT (1) | PT2501704E (enExample) |
| RS (1) | RS53017B (enExample) |
| SI (1) | SI2501704T1 (enExample) |
| WO (1) | WO2011060217A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201401661RA (en) | 2009-12-04 | 2014-07-30 | Sunovion Pharmaceuticals Inc | Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders |
| TWI582096B (zh) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物 |
| TW201416370A (zh) | 2012-07-31 | 2014-05-01 | Lilly Co Eli | 用於治療焦慮之orl-1受體拮抗劑 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| JO3638B1 (ar) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | مركبات مفيدة في تثبيط ror - جاما- t |
| CN110087687A (zh) | 2016-07-29 | 2019-08-02 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
| CA3032302A1 (en) | 2016-07-29 | 2018-02-01 | Taleen G. Hanania | Compounds and compositions and uses thereof |
| AU2017309725A1 (en) | 2016-08-10 | 2019-02-21 | Bayer Cropscience Aktiengesellschaft | Substituted 2-heterocyclyl imidazolyl-carboxamides as pest control agents |
| JP7146782B2 (ja) | 2017-02-16 | 2022-10-04 | サノビオン ファーマシューティカルズ インク | 統合失調症を処置する方法 |
| LT3589638T (lt) | 2017-03-02 | 2021-06-10 | Eli Lilly And Company | Junginiai, naudingi ror-gama-t slopinimui |
| JP6766274B2 (ja) * | 2017-03-02 | 2020-10-07 | イーライ リリー アンド カンパニー | Ror−ガンマ−tを阻害するのに有用な化合物 |
| CN111183138A (zh) | 2017-08-02 | 2020-05-19 | 赛诺维信制药公司 | 异色满化合物以及用途 |
| KR102746817B1 (ko) | 2018-02-16 | 2024-12-24 | 스미토모 파마 아메리카, 인크. | 염, 결정 형태 및 이들의 제조 방법 |
| CA3121910A1 (en) | 2018-12-17 | 2020-06-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
| AU2021257786A1 (en) | 2020-04-14 | 2022-11-03 | Sunovion Pharmaceuticals Inc. | (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine for treating neurological and psychiatric disorders |
| IL318169A (en) | 2020-08-26 | 2025-03-01 | Vertex Pharma | Apol1 inhibitors and methods of use are the same |
| AU2023218994A1 (en) * | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003095427A1 (ja) | 2002-05-10 | 2005-09-15 | 大正製薬株式会社 | スピロ環化合物 |
| WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| CA2563164A1 (en) * | 2004-03-29 | 2005-10-06 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
| DE102004039382A1 (de) * | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| JP2008542375A (ja) * | 2005-06-02 | 2008-11-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Orl−1受容体モジュレーターとして有用な新規3−スピロ環式インドリル誘導体 |
-
2010
- 2010-11-12 US US13/504,176 patent/US20120214784A1/en not_active Abandoned
- 2010-11-12 MX MX2012005690A patent/MX2012005690A/es active IP Right Grant
- 2010-11-12 CN CN201080051845.3A patent/CN102666550B/zh not_active Expired - Fee Related
- 2010-11-12 AU AU2010319400A patent/AU2010319400B2/en not_active Ceased
- 2010-11-12 RS RS20130484A patent/RS53017B/sr unknown
- 2010-11-12 SI SI201030389T patent/SI2501704T1/sl unknown
- 2010-11-12 EP EP10782486.4A patent/EP2501704B1/en active Active
- 2010-11-12 WO PCT/US2010/056449 patent/WO2011060217A1/en not_active Ceased
- 2010-11-12 EA EA201290355A patent/EA020391B1/ru not_active IP Right Cessation
- 2010-11-12 PL PL10782486T patent/PL2501704T3/pl unknown
- 2010-11-12 DK DK10782486.4T patent/DK2501704T3/da active
- 2010-11-12 BR BR112012011710A patent/BR112012011710A2/pt active Search and Examination
- 2010-11-12 ES ES10782486T patent/ES2436241T3/es active Active
- 2010-11-12 CA CA2781041A patent/CA2781041C/en not_active Expired - Fee Related
- 2010-11-12 KR KR1020127012503A patent/KR101368130B1/ko not_active Expired - Fee Related
- 2010-11-12 HR HRP20130969AT patent/HRP20130969T1/hr unknown
- 2010-11-12 PT PT107824864T patent/PT2501704E/pt unknown
- 2010-11-12 JP JP2012538997A patent/JP5723381B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012005690A (es) | 2012-06-13 |
| CA2781041C (en) | 2015-01-06 |
| AU2010319400A1 (en) | 2012-06-07 |
| EA020391B1 (ru) | 2014-10-30 |
| AU2010319400B2 (en) | 2013-12-19 |
| CA2781041A1 (en) | 2011-05-19 |
| HRP20130969T1 (hr) | 2013-11-22 |
| PT2501704E (pt) | 2013-12-05 |
| KR101368130B1 (ko) | 2014-02-27 |
| DK2501704T3 (da) | 2013-10-14 |
| US20120214784A1 (en) | 2012-08-23 |
| EP2501704B1 (en) | 2013-09-18 |
| KR20120082927A (ko) | 2012-07-24 |
| WO2011060217A1 (en) | 2011-05-19 |
| ES2436241T3 (es) | 2013-12-27 |
| CN102666550A (zh) | 2012-09-12 |
| CN102666550B (zh) | 2015-07-15 |
| RS53017B (sr) | 2014-04-30 |
| EA201290355A1 (ru) | 2012-10-30 |
| EP2501704A1 (en) | 2012-09-26 |
| SI2501704T1 (sl) | 2013-11-29 |
| BR112012011710A2 (pt) | 2016-03-01 |
| JP2013510870A (ja) | 2013-03-28 |
| PL2501704T3 (pl) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5723381B2 (ja) | Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 | |
| JP5680101B2 (ja) | Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 | |
| US20240417407A1 (en) | Furoindazole derivatives as gpr84 antagonists | |
| KR20180073638A (ko) | 통증에 대해 활성을 갖는 옥사-디아자스피로 화합물들 | |
| HK1169988B (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
| TW200524608A (en) | Therapeutic agents | |
| BR112012012150A2 (pt) | compostos spiro piperidina como antagonistas de recep-tor orl-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131004 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140930 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150317 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150327 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5723381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |